Russell E Ware

List of Publications by Year
in descending order

247 papers	12,463 citations	38742 50 h-index	27406 106 g-index
253 all docs	253 docs citations	253 times ranked	7455 citing authors

#	Article	IF	Citations
1	Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. MBio, 2022, 13, e0344421.	4.1	7
2	Reproductive equity: preserve the reserve. Blood, 2022, 139, 963-965.	1.4	4
3	US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer, 2022, 69, e29679.	1.5	2
4	New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer, 2022, 69, .	1.5	2
5	Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014â€“2019. Tropical Medicine and International Health, 2021, 26, 23-32.	2.3	10
6	Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. Journal of Clinical Pharmacology, 2021, 61, 547-554.	2.0	3
7	Absence of hydroxyureaâ€induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology, 2021, 194, 252-266.	2.5	23
8	Thereâ€™s safety in numbers. Blood, 2021, 137, 729-731.	1.4	1
9	Implementation of nearâ€universal hydroxyurea uptake among children with sickle cell anemia: A singleâ€center experience. Pediatric Blood and Cancer, 2021, 68, e29008.	1.5	5
10	Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology, 2021, 12, 636609.	2.8	7
11	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
12	Newborn screening for sickle cell disease in subâ€Saharan Africa: Is the glass halfâ€full yet?. Pediatric Blood and Cancer, 2021, 68, e29137.	1.5	2
13	Microscope diagnosis of MYH9-related thrombocytopenia. Blood, 2021, 138, 1000-1000.	1.4	5
14	Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health, 2021, 66, 629338.	2.3	4
15	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokineticsâ€guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology, 2021, 194, 617-625.	2.5	16
16	Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology, 2021, 195, 612-620.	2.5	10
17	Increased oxygen affinity: to have and to hold. Blood, 2021, 138, 1094-1095.	1.4	4
18	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2.5	4

#	Article	IF	Citations
19	Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology, 2021, 194, 970-979.	2.5	22
20	Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine, 2021, 10, 1303.	0.6	6
21	Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases, 2021, 90, 102576.	1.4	2
22	Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances, 2021, 5, 4710-4720.	5.2	13
23	Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines, 2021, 9, 6.	3.2	8
24	Effect of Hydroxyurea Therapy on the Incidence of Infections in Ugandan Children with Sickle Cell Anaemia. Blood, 2021, 138, 765-765.	1.4	1
25	Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. Blood, 2021, 138, 980-980.	1.4	0
26	Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience. Blood, 2021, 138, 11-11.	1.4	5
27	Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer, 2020, 67, e27830.	1.5	3
28	AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine, 2020, 18, 337.	5.5	2
29	Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica, 2020, 105, e272-e275.	3.5	21
30	Î²â€Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular Genetics & Genomic Medicine, 2020, 8, e1294.	1.2	5
31	Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics, 2020, 11, 253-268.	1.2	32
32	Novel dose escalation to predict treatment with hydroxyurea (<scp>NDEPTH</scp>): A randomized controlled trial of a doseâ€prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology, 2020, 95, E242-E244.	4.1	5
33	Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology, 2020, 27, 172-180.	2.5	34
34	Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine, 2020, 382, 2524-2533.	27.0	72
35	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). Journal of Pediatrics, 2020, 222, 236-239.	1.8	11
36	Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization, 2020, 98, 859-868.	3.3	12

#	Article	IF	Citations
37	Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience. Blood, 2020, 136, 17-18.	1.4	0
38	Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia. Blood, 2020, 136, 20-21.	1.4	2
39	Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia. Blood, 2020, 136, 33-34.	1.4	0
40	Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment. Blood, 2020, 136, 8-9.	1.4	1
41	Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience. Blood, 2020, 136, 17-17.	1.4	1
42	Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood, 2020, 136, 16-17.	1.4	0
43	Genetic Basis of Erythrocyte Alloimmunization Among Children with Sickle Cell Anemia in the Dominican Republic. Blood, 2020, 136, 28-29.	1.4	0
44	Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience. Blood, 2020, 136, 34-34.	1.4	0
45	Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2019, 41, 56-63.	0.6	11
46	Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials, 2019, 20, 460.	1.6	7
47	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
48	Sickle cell screening in Uganda: High burden, human immunodeficiency virus comorbidity, and genetic modifiers. Pediatric Blood and Cancer, 2019, 66, e27807.	1.5	12
49	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology, 2019, 94, 871-879.	4.1	51
50	Your tired, your poor, your huddled masses. Blood, 2019, 133, 2010-2011.	1.4	0
51	Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatric Blood and Cancer, 2019, 66, e27778.	1.5	18
52	Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. Pediatric Blood and Cancer, 2019, 66, e27717.	1.5	9
53	Pediatric Hematology. Hematology/Oncology Clinics of North America, 2019, 33, xiii-xiv.	2.2	1
54	Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings. Pediatrics, 2019, 144, e20191681.	2.1	2

#	Article	IF	Citations
55	Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine, 2019, 380, 121-131.	27.0	200
56	Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood, 2019, 134, 1003-1003.	1.4	6
57	Stroke Avoidance for Children in RepÃºblica Dominicana (SACRED):a Prospective Trial to Reduce Stroke in Children with Sickle Cell Anemia. Blood, 2019, 134, 2285-2285.	1.4	0
58	Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy. Blood, 2019, 134, 892-892.	1.4	10
59	Hydroxyurea Therapy to Prevent Incident Stroke Among Children with Sickle Cell Anaemia in Jamaica: The Extend Trial. Blood, 2019, 134, 2269-2269.	1.4	1
60	Effective screening leads to better outcomes in sickle cell disease. Archives of Disease in Childhood, 2018, 103, archdischild-2017-314175.	1.9	4
61	Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. British Journal of Haematology, 2018, 181, 242-251.	2.5	14
62	Modelâ€based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. British Journal of Clinical Pharmacology, 2018, 84, 1410-1412.	2.4	1
63	Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Subâ€Saharan Africa. American Journal of Hematology, 2018, 93, 537-545.	4.1	20
64	Children with sickle cell disease migrating to the United States from subâ€Saharan Africa. Pediatric Blood and Cancer, 2018, 65, e27000.	1.5	8
65	Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study. Annals of Hematology, 2018, 97, 239-246.	1.8	29
66	Sickle cell screening in Europe: the time has come. British Journal of Haematology, 2018, 183, 534-535.	2.5	10
67	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances, 2018, 2, 3035-3044.	5.2	25
68	Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial. Blood Advances, 2018, 2, 50-53.	5.2	5
69	Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer, 2018, 65, e27260.	1.5	13
70	Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology, 2018, 55, 102-112.	3.4	11
71	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. Blood, 2018, 132, 507-507.	1.4	1
72	Geospatial Mapping of Sickle Cell Disease in Northwest Tanzania: The Tanzania Sickle Surveillance Study (TS3). Blood, 2018, 132, 3662-3662.	1.4	7

#	Article	IF	Citations
73	Hydroxyurea Exposure in Lactationâ€"a Pharmacokinetics Study (HELPS). Blood, 2018, 132, 3677-3677.	1.4	3
74	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505.	1.4	3
75	Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa. Blood, 2018, 132, 3-3.	1.4	1
76	A Simple, Rapid, and Inexpensive Color-Based Hemoglobin Assay As a Robust Screening Test for Severe Anemia in Limited Resource Settings. Blood, 2018, 132, 4724-4724.	1.4	0
77	Sickle cell disease. Lancet, The, 2017, 390, 311-323.	13.7	639
78	Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood, 2017, 129, 155-161.	1.4	70
79	Reply to iManage: A novel selfâ€management app for sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26358.	1.5	1
80	Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica, 2017, 102, e76-e79.	3.5	15
81	Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood, 2017, 130, 2585-2593.	1.4	101
82	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	4.1	66
83	Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to nonâ€transfused cohorts. American Journal of Hematology, 2017, 92, E637-E639.	4.1	7
84	Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells, Molecules, and Diseases, 2017, 67, 135-142.	1.4	18
85	Clinical Features of Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 1-26.	1.6	12
86	Technological Advances in Sickle Cell Disease. Blood Cells, Molecules, and Diseases, 2017, 67, 102-103.	1.4	4
87	Development and evaluation of iManage: A selfâ€management app coâ€designed by adolescents with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, 139-145.	1.5	84
88	Pilot of the Chronic Disease Self-Management Program for Adolescents and Young Adults With Sickle Cell Disease. Journal of Adolescent Health, 2017, 60, 120-123.	2.5	30
89	Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Advances, 2017, 1, 1414-1422.	5.2	64
90	Prevalence and mapping of sickle cell disease in northwestern Tanzania. Blood Advances, 2017, 1, 26-28.	5.2	5

#	Article	IF	Citations
91	Development of research capacity in sickle cell anemia in Uganda: impact of collaborations. Blood Advances, 2017, 1, 11-13.	5.2	0
92	Towards a point-of-care strip test to diagnose sickle cell anemia. PLoS ONE, 2017, 12, e0177732.	2.5	21
93	Stroke Avoidance for Children in REpÃºblica Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols, 2017, 6, e107.	1.0	5
94	Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM): A Randomized Controlled Trial. Blood, 2017, 130, 759-759.	1.4	1
95	Hemoglobin variants identified in the Uganda Sickle Surveillance Study. Blood Advances, 2016, 1, 93-100.	5.2	7
96	Stable-Isotope Dilution HPLCâ€“Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples. Clinical Chemistry, 2016, 62, 1593-1601.	3.2	31
97	Development of a pharmacokineticâ€guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. British Journal of Clinical Pharmacology, 2016, 81, 742-752.	2.4	35
98	Translating sickle cell guidelines into practice for primary care providers with Project ECHO. Medical Education Online, 2016, 21, 33616.	2.6	23
99	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. British Journal of Haematology, 2016, 175, 331-338.	2.5	26
100	Hydroxyurea Therapy for Children With Sickle Cell Anemia in Subâ€Saharan Africa: Rationale and Design of the REACH Trial. Pediatric Blood and Cancer, 2016, 63, 98-104.	1.5	41
101	Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease. American Journal of Hematology, 2016, 91, 238-242.	4.1	54
102	Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. The Lancet Global Health, 2016, 4, e195-e200.	6.3	116
103	Characteristics of a rapid, pointâ€ofâ€care lateral flow immunoassay for the diagnosis of sickle cell disease. American Journal of Hematology, 2016, 91, 205-210.	4.1	44
104	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
105	Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the <scp>TW</scp>i<scp>TCH</scp> trial. British Journal of Haematology, 2016, 172, 122-130.	2.5	47
106	Original Research: Sickle cell anemia and pediatric strokes: Computational fluid dynamics analysis in the middle cerebral artery. Experimental Biology and Medicine, 2016, 241, 755-765.	2.4	19
107	Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience. Blood, 2016, 128, 1018-1018.	1.4	3
108	Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial. Blood, 2016, 128, 1019-1019.	1.4	4

#	Article	IF	Citations
109	Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial. Blood, 2016, 128, 1274-1274.	1.4	3
110	Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial. Blood, 2016, 128, 202-202.	1.4	3
111	Genetic Causes of Anemia in Malawian Children Less Than 5 Years of Age: Results from the Malawi Demographic and Health Survey. Blood, 2016, 128, 313-313.	1.4	2
112	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. Blood, 2016, 128, 3652-3652.	1.4	2
113	Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS ONE, 2016, 11, e0164364.	2.5	25
114	Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial. JMIR Research Protocols, 2016, 5, e110.	1.0	21
115	EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols, 2016, 5, e185.	1.0	9
116	Genetic Analyses in the Uganda Sickle Surveillance Study: Modifiers of Sickle Cell Anemia and Identification of Hemoglobin Variants. Blood, 2016, 128, 2479-2479.	1.4	0
117	Using Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest. Blood, 2016, 128, 5923-5923.	1.4	0
118	Optimizing hydroxyurea therapy for sickle cell anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 436-443.	2.5	37
119	Evidence gaps in the management of sickle cell disease: A summary of needed research. American Journal of Hematology, 2015, 90, 273-275.	4.1	37
120	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology, 2015, 90, 806-810.	4.1	21
121	Prevention of conversion to abnormal transcranial <scp>D</scp>oppler with hydroxyurea in sickle cell anemia: A <scp>P</scp>hase III international randomized clinical trial. American Journal of Hematology, 2015, 90, 1099-1105.	4.1	59
122	Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatric Blood and Cancer, 2015, 62, 184-185.	1.5	16
123	A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program forÂSickle Cell Anemia in the Republic of Angola. Journal of Pediatrics, 2015, 167, 1314-1319.	1.8	41
124	Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology, 2015, 169, 262-266.	2.5	17
125	An accurate and inexpensive colorâ€based assay for detecting severe anemia in a limitedâ€resource setting. American Journal of Hematology, 2015, 90, 1122-1127.	4.1	15
126	Hydroxyurea therapy for sickle cell anemia. Expert Opinion on Drug Safety, 2015, 14, 1749-1758.	2.4	172

#	Article	IF	Citations
127	Optimizing hydroxyurea therapy for sickle cell anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 436-443.	2.5	20
128	Accuracy of a Rapid and Simple Point-of-Care Test for Sickle Cell Disease. Blood, 2015, 126, 2182-2182.	1.4	1
129	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
130	Pharmacokinetics and Tissue Distribution of Hydroxyurea in a Mouse Model. Blood, 2015, 126, 4579-4579.	1.4	1
131	Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia. Blood, 2015, 126, 3393-3393.	1.4	0
132	Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. Blood, 2015, 126, 982-982.	1.4	0
133	Ndepth: Novel Dose Escalation to Predict Treatment with Hydroxyurea. Blood, 2015, 126, 3419-3419.	1.4	2
134	Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients. Blood, 2015, 126, 3341-3341.	1.4	0
135	Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. Blood, 2015, 126, 2165-2165.	1.4	1
136	Management of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1033.	7.4	1,189
137	From Infancy to Adolescence. Medicine (United States), 2014, 93, e215.	1.0	59
138	Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. Pediatrics, 2014, 134, 686-695.	2.1	37
139	Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood, 2014, 124, 891-898.	1.4	75
140	Hydroxyurea Pharmacokinetics for Predicting Maximum Tolerated Dose in Children with Sickle Cell Anemia. Blood, 2014, 124, 2707-2707.	1.4	1
141	Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial. Blood, 2014, 124, 4052-4052.	1.4	7
142	An Accurate and Rapid Color-Based Point-of-Care Assay for the Detection of Severe Anemia in Low Resource Settings. Blood, 2014, 124, 688-688.	1.4	1
143	Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia. Blood, 2014, 124, 85-85.	1.4	4
144	Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial. Blood, 2014, 124, 87-87.	1.4	7

#	Article	IF	Citations
145	Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia. PLoS ONE, 2014, 9, e110740.	2.5	28
146	Hydroxyurea Improves Oxygen Transport Effectiveness in Sickle Cell Anemia Patients. Blood, 2014, 124, 2716-2716.	1.4	0
147	Elevated Tricuspid Regurgitation Jet Velocity in Patients with Sickling and Non-Sickling Hemolytic Anemias: Prevalence and Correlates. Blood, 2014, 124, 4906-4906.	1.4	0
148	Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia. Blood, 2014, 124, 89-89.	1.4	0
149	Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood, 2013, 121, 3237-3245.	1.4	59
150	Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 820-830.	2.0	127
151	Is Sickle Cell Anemia a Neglected Tropical Disease?. PLoS Neglected Tropical Diseases, 2013, 7, e2120.	3.0	53
152	A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. American Journal of Hematology, 2013, 88, 984-989.	4.1	89
153	Extrahepatic Iron Deposition In Chronically Transfused Children With Sickle Cell Anemia â€“ Baseline Findings From The Twitch Trial. Blood, 2013, 122, 2238-2238.	1.4	5
154	Successful Outcomes Of An Infant Sickle Cell Clinic In Luanda, Angola. Blood, 2013, 122, 2934-2934.	1.4	2
155	Cost-Effectiveness Of Neonatal Screening For Sickle Cell Disease In The Republic Of Angola. Blood, 2013, 122, 421-421.	1.4	2
156	FOXO3 Variants Are Associated With Lower Fetal Hemoglobin Levels In Children With Sickle Cell Disease. Blood, 2013, 122, 778-778.	1.4	1
157	Liver Iron Concentration By MRI In Chronically Transfused Children With Sickle Cell Anemia In The Twitch Trial. Blood, 2013, 122, 780-780.	1.4	0
158	Effect Of Genetic Modifiers Of Baseline Fetal Hemoglobin On Hydroxyurea Response In Children With Sickle Cell Disease. Blood, 2013, 122, 2216-2216.	1.4	0
159	Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood, 2012, 119, 4587-4596.	1.4	262
160	Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood, 2012, 119, 3925-3932.	1.4	308
161	Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 2012, 120, 4304-4310.	1.4	204
162	Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 170-172.	1.5	13

#	Article	IF	Citations
163	Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABYâ€HUG phase III clinical trial. Pediatric Blood and Cancer, 2012, 59, 254-257.	1.5	42
164	Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology, 2012, 87, 428-430.	4.1	38
165	Genetic Predictors of Hemoglobin F Response to Hydroxyurea in Sickle Cell Anemia. Blood, 2012, 120, 241-241.	1.4	5
166	Effects of Hydroxyurea (HU) On Lymphocyte Subsets and the Immune Response to Pneumococcal, Measles, Mumps and Rubella Vaccination in the Pediatric Hydroxyurea Phase III Clinical Trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood, 2012, 120, 243-243.	1.4	6
167	A Prospective Pilot Newborn Screening and Treatment Program for Sickle Cell Anemia in the Republic of Angola. Blood, 2012, 120, 480-480.	1.4	7
168	Increased Erythrocyte Rigidity Is Sufficient to Cause Endothelial Dysfunction in Sickle Cell Disease. Blood, 2012, 120, 818-818.	1.4	12
169	Gene Expression Profiles of Hydroxyurea Tolerant Cell Lines Identify Genetic Mechanisms That Influence Hydroxyurea Maximum Tolerated Dose. Blood, 2012, 120, 1005-1005.	1.4	2
170	Identification of Genetic Modifiers Associated with Risk of Stroke in Children with Sickle Cell Anemia. Blood, 2012, 120, 3228-3228.	1.4	0
171	Organic Anion Transporting Polypeptide 1B (OATP1B) Transporters Modulate Hydroxyurea Pharmacokinetics. Blood, 2012, 120, 1008-1008.	1.4	0
172	Cost and Reliability of Two Methods of Hemoglobin Identification for Sickle Cell Newborn Screening in the Republic of Angola. Blood, 2012, 120, 2064-2064.	1.4	7
173	Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, The, 2011, 377, 1663-1672.	13.7	647
174	Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?. Current Opinion in Hematology, 2011, 18, 158-165.	2.5	131
175	Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood, 2011, 118, 4985-4991.	1.4	139
176	Genetic predictors for stroke in children with sickle cell anemia. Blood, 2011, 117, 6681-6684.	1.4	119
177	Chromosome damage and repair in children with sickle cell anaemia and longâ€term hydroxycarbamide exposure. British Journal of Haematology, 2011, 154, 134-140.	2.5	24
178	Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood and Cancer, 2011, 57, 1011-1017.	1.5	66
179	Longâ€term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. American Journal of Hematology, 2011, 86, 357-361.	4.1	24
180	Therapeutic Phlebotomy in Children with Sickle Cell Anemia, Stroke, and Iron Overload: The SWiTCH Experience. Blood, 2011, 118, 1044-1044.	1.4	1

#	Article	IF	Citations
181	Predicting Hydroxyurea Responses in Children with Sickle Cell Anemia. Blood, 2011, 118, 2131-2131.	1.4	1
182	Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical Trial. Blood, 2011, 118, 8-8.	1.4	1
183	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). Blood, 2011, 118, 2134-2134.	1.4	0
184	How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, 2010, 115, 5300-5311.	1.4	325
185	Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica, 2010, 95, 1599-1603.	3.5	55
186	Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 2010, 116, 687-692.	1.4	187
187	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. Journal of Pediatrics, 2010, 156, 66-70.e1.	1.8	109
188	The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatric Blood and Cancer, 2010, 54, 250-255.	1.5	51
189	Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2010, 698, 38-42.	1.7	51
190	Validation of Genetic Predictors for Stroke In Children with Sickle Cell Anemia. Blood, 2010, 116, 2639-2639.	1.4	1
191	Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). Blood, 2010, 116, 270-270.	1.4	8
192	Stroke with Transfusions Changing to Hydroxyurea (SWiTCH): A Phase 3 Randomized Clinical Trial for Treatment of Children with Sickle Cell Anemia, Previous Stroke, and Iron Overload. Blood, 2010, 116, 844-844.	1.4	10
193	Modulation of MicroRNA Expression In Sickle Reticulocytes Is Associated with Hydroxyurea Treatment and Fetal Hemoglobin Induction. Blood, 2010, 116, 2650-2650.	1.4	1
194	Academic Community Standards for Chronic Transfusion Therapy In Children with Sickle Cell Anemia and Abnormal Transcranial Doppler Velocities. Blood, 2010, 116, 2643-2643.	1.4	0
195	Microarray Analysis of Erythroid Gene Expression In Sickle Cell Anemia Patients Treated with Hydroxyurea.. Blood, 2010, 116, 1623-1623.	1.4	1
196	A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Î²-Thalassemia Intermedia. Blood, 2010, 116, 2078-2078.	1.4	21
197	Advances in the use of hydroxyurea. Hematology American Society of Hematology Education Program, 2009, 2009, 62-69.	2.5	100
198	A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatric Blood and Cancer, 2009, 52, 609-615.	1.5	82

#	Article	IF	Citations
199	R2* magnetic resonance imaging of the liver in patients with iron overload. Blood, 2009, 113, 4853-4855.	1.4	311
200	Glomerular Hyperfiltration and Microalbuminuria in Children with Sickle Cell Anemia.. Blood, 2009, 114, 263-263.	1.4	5
201	Genetic Predictors of Hydroxyurea Response in Children with Sickle Cell Disease.. Blood, 2009, 114, 820-820.	1.4	1
202	Assessment of Genotoxicity Associated with Hydroxyurea Therapy in Children with Sickle Cell Anemia.. Blood, 2009, 114, 2554-2554.	1.4	0
203	Movement of Hydroxyurea Across Cell Membranes Is Mediated by Specific Solute Carrier (SLC) Transporters.. Blood, 2009, 114, 2575-2575.	1.4	0
204	Hydroxyurea Therapy Requires HbF Induction for Clinical Benefit in a Sickle Cell Mouse Model.. Blood, 2009, 114, 817-817.	1.4	1
205	Hydroxyurea Adherence and Associated Outcomes in Medicaid Enrollees with Sickle Cell Disease.. Blood, 2009, 114, 2483-2483.	1.4	0
206	Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood and Cancer, 2008, 50, 293-297.	1.5	81
207	The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British Journal of Haematology, 2008, 142, 94-99.	2.5	50
208	Hydroxyurea for Children with Sickle Cell Disease. Pediatric Clinics of North America, 2008, 55, 483-501.	1.8	59
209	CHEMICAL AND FUNCTIONAL ANALYSIS OF GENERIC HYDROXYUREA FORMULATIONS. Pediatric Hematology and Oncology, 2008, 25, 423-429.	0.8	6
210	Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood, 2007, 110, 1043-1047.	1.4	192
211	Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease. American Journal of Hematology, 2007, 82, 740-743.	4.1	20
212	Quantitative Analysis of Howell-Jolly Bodies in Children with Sickle Cell Disease. Experimental Hematology, 2007, 35, 179-183.	0.4	66
213	Principles and indications of chronic transfusion therapy for children with sickle cell disease. Clinical Advances in Hematology and Oncology, 2007, 5, 686-8.	0.3	3
214	Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 2005, 106, 2269-2275.	1.4	251
215	Is there a little PNH in all of us?. Blood, 2005, 105, 3760-3761.	1.4	3
216	Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatric Blood and Cancer, 2005, 45, 982-985.	1.5	93

#	Article	IF	Citations
217	Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. Journal of Pediatrics, 2004, 145, 346-352.	1.8	168
218	Chemical and Functional Analysis of Hydroxyurea Oral Solutions. Journal of Pediatric Hematology/Oncology, 2004, 26, 179-184.	0.6	37
219	Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 2004, 103, 2039-2045.	1.4	306
220	Malignancy in patients with sickle cell disease. American Journal of Hematology, 2003, 74, 249-253.	4.1	88
221	Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 2002, 99, 10-14.	1.4	154
222	A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 2001, 139, 790-796.	1.8	165
223	Thrombophilic DNA Mutations As Independent Risk Factors for Stroke and Avascular Necrosis in Sickle Cell Anemia. Hematology, 2001, 6, 347-353.	1.5	6
224	Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV antiâ€Ð and to IV gammaglobulin predict response to subsequent splenectomy?. American Journal of Hematology, 2001, 67, 27-33.	4.1	44
225	Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood, 2000, 95, 3589-3593.	1.4	114
226	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 1855-1865.	27.0	1,062
227	Hydroxyurea as an Alternative to Blood Transfusions for the Prevention of Recurrent Stroke in Children With Sickle Cell Disease. Blood, 1999, 94, 3022-3026.	1.4	148
228	Detection of hemoglobin variants in erythrocytes by flow cytometry. , 1999, 35, 242-248.		26
229	Hemoglobin S/OARAB: Thirteen new cases and review of the literature. , 1999, 60, 279-284.		32
230	Hemoglobin S/OARAB: Thirteen new cases and review of the literature. American Journal of Hematology, 1999, 60, 279-284.	4.1	1
231	Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura. , 1998, 57, 131-138.		18
232	Inherited DNA mutations contributing to thrombotic complications in patients with Sickle cell disease. , 1998, 59, 267-272.		69
233	Oligoclonal expansion of CD45RO+ T lymphocytes in Omenn syndrome. Journal of Clinical Immunology, 1997, 17, 322-332.	3.8	44
234	Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. , 1997, 54, 40-46.		49

#	Article	IF	Citations
235	Tumor necrosis factor-Î± suppresses hematopoiesis in children with myelodysplasia. , 1997, 28, 69-74.		7
236	Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease. , 1996, 26, 48-53.		26
237	Identification and characterization of an inherited mutation of PIG-A in a patient with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 1996, 93, 590-593.	2.5	26
238	Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia. American Journal of Hematology, 1995, 50, 140-143.	4.1	41
239	Phenotypic and functional analysis of lymphocytes in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 1995, 50, 244-253.	4.1	30
240	Urticarial vasculitis: An autoimmune disorder following therapy for Hodgkin's disease. Medical and Pediatric Oncology, 1995, 25, 208-212.	1.0	13
241	Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: implications for the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood, 1994, 83, 3753-7.	1.4	3
242	Hemoglobin sickle-lepore: Report of two siblings and review of the literature. American Journal of Hematology, 1993, 44, 192-195.	4.1	16
243	Transient hypoplastic anemia of childhood. American Journal of Hematology, 1992, 40, 240-241.	4.1	1
244	Transient erythroblastopenia in the first year of life. American Journal of Hematology, 1991, 37, 156-158.	4.1	18
245	Familial erythrophagocytic lymphohistiocytosis: Late relapse despite continuous high-dose VP-16 chemotherapy. Medical and Pediatric Oncology, 1990, 18, 27-29.	1.0	12
246	Congenital Pelger-Huet anomaly in triplets. American Journal of Hematology, 1988, 27, 226-227.	4.1	5
247	Childhood hepatic mesenchymoma: Successful treatment with surgery and multiple-agent chemotherapy. Medical and Pediatric Oncology, 1988, 16, 62-65.	1.0	34